Duchenne muscular dystrophy. Muscular dystrophy
Conditions
Interventions
Intervention group: 100 to 150 cc of SVF product containing 20% mesenchymal cells, 60% progenitor cells and 20% other autologous cells in albumin medium will be injected intravenously through peripher
Sponsors
Research Deputy of Islamic Azad University, Tehran Medical Branch
Eligibility
Sex/Gender
Male
Age
7 Years to 30 Years
Inclusion criteria
Inclusion criteria: Genetic evidence of Duchenne disease as a cause of myopathy The patient's ability to walk is not completely lost and the use of assistive devices such as canes and walkers is not permanent. The patient's muscle strength is decreasing Willingness and satisfaction to participate in the study by the patient's legal guardian in decision making and willingness to participate regularly in follow-up courses
Exclusion criteria
Exclusion criteria: Advanced motor impairment leading to permanent use of crutches, walkers and wheelchairs A history of known malignancy History of associated genetic and non-genetic degenerative diseases Having blood and internal diseases that increase the risk of liposuction and anesthesia required A history of any other acute or chronic illness that, at the discretion of the clinician responsible for implementing the plan, prevents the patient from entering the study. Insufficient volume of subcutaneous fat or the presence of concomitant injuries in the abdomen in the initial examination that make it difficult to obtain adipose tissue to prepare SVF.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory Function. Timepoint: 1, 3, 6, 9 and 12 month after injection. Method of measurement: Spirometery.;Muscular Force. Timepoint: First every 14 days to 1 month, then Every 1 month to 1 year. Method of measurement: Physical Exam.;Cardiac Function. Timepoint: 1, 3, 6, 9 and 12 month after injection. Method of measurement: Echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscular Enzymes. Timepoint: 1, 3, 6, 9 and 12 month after injection. Method of measurement: Lab Data. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKhadijeh Hajinaghi Tehrani
Bu-ali Hospital
Outcome results
None listed